149289-29-2

Usage

Uses

Used in Pharmaceutical Industry:
1-[2-amino-1-(4-hydroxyphenyl)ethyl]cyclohexanol is used as a lead compound for the development of new drugs targeting various medical conditions. Its unique structure allows it to potentially modulate multiple biological pathways and interact with different receptors, making it a versatile candidate for drug discovery.
Used in Antidepressant Applications:
As a metabolite of Venlafaxine, a selective serotonin noradrenaline reuptake inhibitor, 1-[2-amino-1-(4-hydroxyphenyl)ethyl]cyclohexanol is used as an antidepressant. It is believed to contribute to the therapeutic effects of Venlafaxine by modulating the levels of serotonin and noradrenaline in the brain, thereby helping to alleviate symptoms of depression and anxiety.
Used in Drug Delivery Systems:
1-[2-amino-1-(4-hydroxyphenyl)ethyl]cyclohexanol can also be utilized in the development of drug delivery systems, where its ability to form hydrogen bonds and interact with biological targets can be exploited to improve the delivery, bioavailability, and efficacy of various therapeutic agents. This application could be particularly useful in enhancing the performance of existing drugs or in the development of novel therapeutic strategies.

Upstream product

• 26960-77-0 sodium dodecanethiolate 
• 93413-77-5 N,N-didesmethylvenlafaxine 
• 14191-95-8 4-cyanomethylphenol 
• 104-47-2 p-methoxybenzylnitrile 
• 108-94-1 cyclohexanone 
• 93413-76-4 1-[cyano(4-methoxyphenyl)methyl]cyclohexanol 
• 130198-05-9 1-[2-amino-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride 

Downstream Products

• 93413-62-8 O-desmethylvenlafaxine 
• 1168135-16-7 1-[2-amino-1-(4-benzyloxyphenyl)ethyl]cyclohexanol 
• 1076199-24-0 tert-butyl 2-(4-(benzyloxy)phenyl)-2-(1-hydroxycyclohexyl)carbamate 

Relevant academic research and scientific papers

Synthesis method of venlafaxine

The invention relates to the technical field of drug synthesis, in particular to a synthesis method of venlafaxine. The synthesis method comprises first steps of using p-hydroxyphenylacetonitrile as a raw material, adding an activator under anhydrous conditions, and reacting with cyclohexanone to obtain 2 -cyclohexylene -2 - (4 hydroxybenzene) acetonitrile. 2nd-Step: 2 - Cyclohexylene -2 - (4 hydroxybenzene) acetonitrile was oxidized with peracetic acid to give an epoxy compound. 3rd: The epoxy compound is added with catalyst Raney nickel, potassium hydroxide assisted catalysis and high pressure hydrogenation to obtain amino. 4th: The amino is then reacted Eschweiler-Clarke, i.e. the amino is reacted with a - formaldehyde system in formic acid to give a desvenlafaxine. The method has the advantages of high environmental friendliness, low production cost, simple steps, mild reaction conditions and high total yield of 74% or more, and is suitable for large-scale industrial production.

Method for industrially synthesizing desvenlafaxine

The invention provides a method for industrially synthesizing desvenlafaxine. The method is a new technology including the steps that 4-hydroxybenzyl cyanide serves as a starting raw material and is subjected to hydroxyl protection, a condensation reaction, pressurized hydrogenation and an Eschweiler-Clark reaction, and the desvenlafaxine is obtained. The method is small in step number, easy and convenient to operate, high in yield and low in cost, and the product is easy to separate and purify; adopted reagents are all common reagents, and the method is a new technology suitable for industrial production.

DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME

Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

CRYSTAL FORMS OF O-DESMETHYLVENLAFAXINE FUMARATE

Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical composition thereof.

PROCESS FOR SYNTHESIZING DESVENLAFAXINE FREE BASE AND SALTS OR SOLVATES THEREOF

The invention relates generally to an improved process for manufacturing desvenlafaxine free base and salts or solvates thereof.

Processes for the preparation of odesmethylvenlafaxine, free from its dimer impurities

The present invention provides isolated O-desmethylvenlafaxine impurities ODV-Dimer and ODV-N-Dimer, their use as a reference marker and reference standard, and a process for the preparation of O-desmethylvenlafaxine free from said impurities

Processes for the synthesis of O-desmethylvenlafaxine

The present invention describes processes for the preparation of O-desmethylvenlafaxine and tridesmethylvenlafaxine, which may be used as an intermediate in preparing O-desmethylvenlafaxine.

PROCESS FOR PREPARATION OF 0-DESMETHYLVENLAFAXINE AND ITS ANALOGUES

The present invention belongs to the field of organic chemistry and refers to a process for the preparation of O-desmethylvenlafaxine (l-[2-Dimethylamino)-l-(4-hydroxyphenyl)ethyl]cyclo- hexanol), its analogues and pharmaceutical acceptable salts thereof. The invention also relates to a catalytic hydrogenation of cyano-group of the substituted acetonitrile.

SUBSTANTIALLY PURE O-DESMETHYLVENLAFAXINE AND PROCESSES FOR PREPARING IT

Methods for preparing substantially pure O-desmethylvenlafaxine are described.